Johnson & Johnson vs Zimmer Biomet Holdings, Inc. — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
6.9
Neutral
Quality
Health
Growth
Valuation
Sentiment
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
ZBH
Earnings growing 34% year-over-year on 9% revenue growth.
⚠ cautious analyst consensus — few Buy ratings.
Analyst Consensus
BUY
Target $252.42 (+11.1%)
24 analysts
HOLD
Target $98.52 (+18.8%)
21 analysts
Fundamentals
JNJ
ZBH
26.3×
Trailing P/E
21.5×
17.9×
Forward P/E
9.2×
21.8%
Profit Margin
9.1%
68.0%
Gross Margin
70.2%
26.4%
ROE
6.1%
9.9%
Revenue Growth
9.3%
-52.9%
Earnings Growth
34.1%
0.33
Beta
0.61
—
Price / Book
—
$546.9B
Market Cap
$16.0B
$146 – $252
52-Week Range
$80 – $108
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →